<p><i>In vitro</i> efficacy of Maraviroc in MDM cultures. The bars represents the percentage of viral inhibition (p24 production pg/ml) in presence of Maraviroc, AMD3100 and AZT at different concentrations, considering the untreated as 100. Mean values of at least 3 experiments for each isolate are shown. Error bars indicating inter-experimental standard deviations are shown. Maraviroc median IC<sub>50</sub> and IC<sub>90</sub> values of 3 different experiments are also shown. The False Positive Rate (FPR) values are based on the V3 sequences and calculated with Geno2Pheno algorithm. The phenotypic tropism was evaluated on astroglioma U87MG-CD4<sup>+</sup>-CCR5<sup>+</sup>−/CXCR4<sup>+</sup>-expressing cells (DR: R5<sup>+</sup>X4; D: R5/X4;...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>+/- values represent the standard errors of triplicates. Results are representative of two indepe...
<p>(a) MDM, PBMC and MDDC were treated with 500 IU/ml IFNα 24 hr prior to challenge with HIV-1 89.6....
<p><i>In vitro</i> efficacy of Maraviroc in PBMC cultures. The histogram represents the percentage o...
<p>The bars represents the percentage of HIV-1 DNA copies and p24 values (normalized per 10<sup>6</s...
<p>The bars represents the percentages of HIV-1 isolate replication in MDM cultures infected with 8,...
<p>The bars represents the percentages of HIV-1 isolate replication in PBMC cultures infected with 1...
<p>MAGIC-5 cells were infected with pseudotyped viruses in the absence or presence of 1 µM maraviroc...
(A) Change in viral load (◊ dashed line) and CD4 (▪ solid line) for participant 3, who received mara...
<p>In each graph, the percentages of inhibition relative to the extent of virus replication in the n...
Maraviroc (Pfizer's UK-427857, Selzentry or Celsentri outside the USA) is the first agent in the new...
Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study,...
Maraviroc belongs to a new class of anti-HIV drugs named CCR5 antagonists, which block HIV entry int...
Abstract Objective Few data are available about the efficacy of maraviroc (MVC) during routine use. ...
International audienceOBJECTIVES: Virological failure (VF) in patients on maraviroc-based treatment ...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>+/- values represent the standard errors of triplicates. Results are representative of two indepe...
<p>(a) MDM, PBMC and MDDC were treated with 500 IU/ml IFNα 24 hr prior to challenge with HIV-1 89.6....
<p><i>In vitro</i> efficacy of Maraviroc in PBMC cultures. The histogram represents the percentage o...
<p>The bars represents the percentage of HIV-1 DNA copies and p24 values (normalized per 10<sup>6</s...
<p>The bars represents the percentages of HIV-1 isolate replication in MDM cultures infected with 8,...
<p>The bars represents the percentages of HIV-1 isolate replication in PBMC cultures infected with 1...
<p>MAGIC-5 cells were infected with pseudotyped viruses in the absence or presence of 1 µM maraviroc...
(A) Change in viral load (◊ dashed line) and CD4 (▪ solid line) for participant 3, who received mara...
<p>In each graph, the percentages of inhibition relative to the extent of virus replication in the n...
Maraviroc (Pfizer's UK-427857, Selzentry or Celsentri outside the USA) is the first agent in the new...
Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study,...
Maraviroc belongs to a new class of anti-HIV drugs named CCR5 antagonists, which block HIV entry int...
Abstract Objective Few data are available about the efficacy of maraviroc (MVC) during routine use. ...
International audienceOBJECTIVES: Virological failure (VF) in patients on maraviroc-based treatment ...
<p>PM1/CCR5 cells (1×10<sup>5</sup>) were infected with 10 ng p24 Gag for 3 h in the presence or abs...
<p>+/- values represent the standard errors of triplicates. Results are representative of two indepe...
<p>(a) MDM, PBMC and MDDC were treated with 500 IU/ml IFNα 24 hr prior to challenge with HIV-1 89.6....